Common semaglutide concerns — and what the clinical evidence says

The trial data: how strong is the evidence base?

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight and at least one weight-related condition to 2.4mg semaglutide weekly or placebo over 68 weeks. Participants lost an average of around 15% of body weight, a result that, at the time, set a new benchmark for a licensed medicine. That figure comes from a rigorous, placebo-controlled design, not a manufacturer press release, and it underpins the MHRA's decision to license Wegovy for weight management in the UK.

The same trial is where most documented concerns originate. Gastrointestinal events (nausea, vomiting, diarrhoea, constipation, reflux) were reported by a substantial proportion of participants on semaglutide. Most were mild to moderate and tended to ease after the first weeks at a given dose. Serious adverse events were infrequent but present. The trial was designed to find them, which is precisely why the data is credible. You can read the NICE appraisal of semaglutide (NICE technology appraisal TA875) for the committee's own assessment of the trial quality and the trade-offs involved.

One misconception worth addressing gently: some people assume that because semaglutide produces significant weight loss, it must be doing something extreme to the body. If you want a fuller grounding in how semaglutide works as a medicine, including its mechanism and licensed uses, our dedicated page covers that in detail. The trial results are large by historical standards for a medicine, but the mechanism is grounded in normal physiology.

Which semaglutide concerns does the MHRA specifically flag?

The MHRA monitors licensed medicines continuously, and semaglutide carries a Black Triangle (▼) status, meaning additional surveillance is in place and healthcare professionals are asked to report any suspected side effects promptly. The Yellow Card scheme allows patients to do the same.

In January 2026, the MHRA issued a Drug Safety Update covering GLP-1 receptor agonists, including semaglutide, highlighting acute pancreatitis as a known but infrequent risk that can be serious. The symptom to act on: severe stomach pain, persistent, possibly spreading to the back, with or without vomiting. That warrants urgent medical attention rather than waiting for your next appointment. The MHRA did not withdraw the medicines or restrict access, the update was a clear communication of a documented risk so that patients and prescribers could recognise it early.

Other signals the regulator tracks include gallbladder disease, dehydration from prolonged GI illness, and (in people with pre-existing diabetic eye disease) possible changes in retinal status. These are not reasons to avoid semaglutide if it is clinically appropriate; they are reasons to start with a thorough clinical assessment and maintain contact with your prescriber throughout. Our clinical team reviews every case before supply and before every repeat, specifically to catch these considerations.

Concerns about longer-term use and stopping treatment

A frequently raised worry is what happens over time: does the body adapt? And what happens when treatment stops? The honest answer is that long-term data beyond two years is still accumulating. Understanding semaglutide at the 1mg dose level, including how titration works and why dose steps matter, can help clarify what longer-term use actually involves in practice. Privately prescribed semaglutide is not subject to the same two-year limit, it is reviewed clinically at each repeat.

On stopping: most trial evidence suggests weight tends to return gradually once treatment ends, which reflects the biological nature of obesity rather than a unique danger of the medicine itself. That is a real concern and a clinical consideration worth discussing with a prescriber rather than treating as a reason to avoid starting. If you want to explore how semaglutide compares with other options, the weight loss treatment overview covers the landscape.

For a closer look at the specific trade-offs people weigh up, the drawbacks of semaglutide page goes through the most commonly cited ones in detail. And if you are thinking about how semaglutide is formulated and why that matters for how it is absorbed, there is a dedicated explanation of that too.

Who should not use semaglutide, and how concerns shape eligibility

Some concerns translate directly into contraindications. Semaglutide is not recommended during pregnancy, breastfeeding, or if you are actively trying to conceive. It is not licensed for use in people under 18. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 requires a prescriber to decline or defer treatment. Certain gastrointestinal conditions and a history of pancreatitis call for careful prescriber judgement rather than automatic exclusion, but they are always part of the assessment.

The licensed eligibility threshold is a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. For some ethnic backgrounds, UK guidance applies a threshold 2.5 kg/m² lower than the standard figures. A BMI figure that technically qualifies does not guarantee that treatment is appropriate, the prescriber's job is to weigh the full picture, including any conditions that create additional risk.

If you have questions after reading this, the frequently asked questions page covers many of the practical details people raise before starting. For concerns about interactions with other medicines (for example, if you take a stimulant medication alongside Wegovy) there are dedicated pages for those specific situations. The right place to resolve an individual concern is always with a prescriber who can see your full history. Check your eligibility through a free consultation and have those questions answered by a real clinician.